Abstract
Thrombosis of transcatheter aortic valve implantation (TAVI) is an uncommon complication that commonly occurs weeks to months following the procedure. Herein are described the details of a patient who presented with a recurrence of symptoms days after intervention with a bioprosthesis thrombosis that was successfully treated with direct oral anticoagulant (DOAC) therapy and resulted in hemodynamic improvement and resolution of symptoms. Whilst a previous trial of DOAC therapy with mechanical valves was stopped due to elevated events in comparison to warfarin, a TAVI valve may be different, and the rapid onset of action and reduced bleeding risk may be beneficial in this patient group.
Publication types
-
Case Reports
-
Video-Audio Media
MeSH terms
-
Administration, Oral
-
Aged, 80 and over
-
Aortic Valve / physiopathology
-
Aortic Valve / surgery*
-
Aortic Valve Stenosis / physiopathology
-
Aortic Valve Stenosis / surgery*
-
Bioprosthesis*
-
Blood Coagulation / drug effects*
-
Echocardiography, Three-Dimensional
-
Echocardiography, Transesophageal
-
Factor Xa Inhibitors / administration & dosage*
-
Heart Valve Prosthesis*
-
Hemodynamics
-
Humans
-
Male
-
Prosthesis Design
-
Rivaroxaban / administration & dosage*
-
Thrombosis / blood
-
Thrombosis / drug therapy*
-
Thrombosis / etiology
-
Time Factors
-
Tomography, X-Ray Computed
-
Transcatheter Aortic Valve Replacement / adverse effects
-
Transcatheter Aortic Valve Replacement / instrumentation*
-
Treatment Outcome
Substances
-
Factor Xa Inhibitors
-
Rivaroxaban